N30 Pharma selects Greenphire's payment tech for cystic fibrosis study
N30 Pharmaceuticals will use Greenphire's global payment technology platforms, eClinicalGPS and ClinCard, to streamline payments to investigators and subjects throughout its phase Ia/IIb cystic fibrosis study that began in March.
Greenphire's payment technology platforms will ensure that clinical trial payments from sponsor to site and from site to subjects are quick, accurate, automated and fully compliant with relevant regulations, including the Sunshine Act. N30 Pharma will use the eClinicalGPS platform to automate payments to investigative sites involved in the trial and the ClinCard platform to reimburse subjects and to arrange subject travel, thereby reducing costs and administrative complexities associated with the trial.
"N30 Pharma is excited to work with Greenphire on this important trial,” said Tom Sokolowski, CFO at N30 Pharma. “Using Greenphire's systems will ensure that our staff and investigators can focus entirely on the scientific and patient-centric elements of the study while remaining confident that payments are accurate, quick, and fully accounted for.”
Sam Whitaker , CEO and co-founder of Greenphire, said, "We are looking forward to collaborating with N30 Pharma on the company's first clinical trial in cystic fibrosis which we hope will eventually result in new, effective treatments for the disease. By using Greenphire's payment platforms to manage the payment and subject travel aspects of the trial, N30 Pharma can reduce costs and risk, remain compliant with relevant regulations and spend less time managing the logistical aspects of the study."